Successful treatment of therapy-refractory chronic wounds with DerMax;Erfolgreiche behandlung therapierefraktärer chronischer wunden mit DerMax

Zeitschrift fur Wundheilung

Volumn 11, Issue 6, 2006, Pages 310-314

  Körber, Andreas ^a   Freise, Julia ^a   Rietkötter, Jost ^a   Grabbe, Stephan ^a   Dissemond, Joachim ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Chronic wound; DerMax ; Leg ulcer; MMP; ROS

Indexed keywords

DERMATOLOGICAL AGENT; MATRIX METALLOPROTEINASE; POLYHYDROGENATED IONOGENE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHRONIC WOUND; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM; FEMALE; GAUZE DRESSING; HUMAN; MALE; OINTMENT; PAIN ASSESSMENT; PH; TREATMENT OUTCOME; WOUND HEALING;

EID: 33845681484     PISSN: 1439670X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dissemond J, Goos M, Wagner SN: Die Rolle von oxidativem Stress in der Pathogenese und Therapie chronischer Wunden. Hautarzt 2002; 53:718-23.
2. Dissemond J, Witthoff M, Brauns TC, Haberer D, Goos M: Untersuchungen zum pH-Wert des Milieus chronischer Wunden im Rahmen einer modernen Wundtherapie. Hautarzt 2002; 54:959-65.
3. Ehresmann U, Gallenkemper G, Hermanns HJ, Herouy Y, Jünger M, Kahle B, Rabe E, Scharffetter-Kochanek K, Schwahn-Schreiber C, Stücker M, Vanscheidt V, Waldermann F, Wilm S. Leitlinie zur Diagnostik und Therapie des Ulcus cruris venosum. Phlebologie 2004; 5:166-85.
4. Gillitzer R: Modernes Wundmanagement. Hautarzt 2002; 53: 130-45.
5. Glibbery A, Mani R: pH in leg ulcers. Int J Microcirc Clin Exp 1992; 11:109.
6. Greener B, Hughes AA, Bannister NP, Douglass J: Proteases and pH in chronic wounds. J Wound Care 2005; 14:59-61.
7. James TJ, Hughes MA, Cherry GW, Taylor RP: Evidence of oxidative stress in chronic venous ulcers. Wound Rep Regen 2003; 11: 172-6.
8. Karim RB, Ahmed AKJ, Brito BLR, Dutrieux RP: Balancing MMP in chronic wounds: a pilot study with DerMax®. OLVG Amsterdam.
9. Lassance FP, Karim RB, Brito B, Raaijmaker J, Joris Hage J (2003) Analysis of morphological and immunhistological changes during treatment with DerMax®. Wound Rep Regen 2002; 11:53.
10. Latha B, Babu M: The involvement of free radicals in burn injury: a review. Burns 2001; 27:309-17.
11. Lohmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H: Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002; 45:1011-6.
12. Mani RAJ: Is wound bed preparation assessably noninvasively? In: International Congress and Symposium Series No. 250, Wound bed preparation. Cherry G, Harding KG, Ryan TJ (eds.), Royal Society of Medicine Press 2000, London, pp. 21-28.
13. Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, Adham M, Connolly CE, Sultan S: The impact of differential expression of extracellular matrix metal loproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 11:106-10.
14. Pirayesh A, Dessy L, Hoksema PT, Ulrich M, Monstrey S: Efficacy of Poly Hydrated Ionogens in Achieving Stable Wound Closure in Recalcitrant Diabetic Foot Ulcers: A Multicentre Pilot Study. WUWHS 2004, Paris H004.
15. Roeb E, Matern S: Matrix-Metallopreoteinasen und kolorektales Karzinom. Med Klin 2005; 98: 763-70.
16. Saarialho-Kere UK: Patterns ot matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998: 7:S47-54.
17. Samuni A, Black CD, Krishna CM, Malech HL, Bernstein EF, Russo A: Hydroxyl radical production by stimulated neutrophils reappraised. J Biol Chem 1988; 27:797-801.
18. Schneider LA, Körber A, Grabbe S, Dissemond J: Influence of pH on wound healing: An overview. Arch Dermatol (in press).
19. Schonfelder U, Abel M, Wiegand C, Klemm D, Elsner P, Hipler UC: Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro. Biomaterials 2005; 26:6664-73.
20. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G: Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repr Regen 1999; 7:442-52.
21. Tsukada K, Tokunaga K, Iwama T, Mishima Y: The pH changes of pressure ulcers related to the healing process of wounds. Wounds 1992; 4:16-20.
22. Vaalamo M, Leivo T, Saarialho-Kere U: Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Hum Pathol 1999; 30: 795-802.
23. van den Berg AJ, Halkes SB, van Ufford HC, Hoekstra MJ, Beukelman CJ. A novel formulation of metal ions and citric acid reduces reactive oxygen species in vitro. J Wound Care 2003; 12:413-8.
24. van Leen MWF, Lüning EWN, Neyens JCL, Schols JMGA, Naaldwijk J: Analysis of morphological and immunohistochemical changes during treatment with Dermax®. WUWHS 2004, Paris.
25. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs. standard treatment in the management of diabetic foot ulcers. Arch Surg 2002: 137:822-7.
26. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen VT: Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996; 106:1119-24.
27. Wysocki AB, Staiano-Coico L, Grinnell F: Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1991; 101:64-8.
28. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK: Wound fluids front human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 107:71996; 43-8.